The FDA has given accelerated approval to tisagenlecleucel (Kymriah®, Novartis) for treatment of patients with relapsed or refractory (R/R) follicular lymphoma (FL) within six months of receiving two or more lines of systemic therapy or if the patient relapsed after an autologous hematopoietic stem cell transplant. "Follicular lymphoma is a common non-Hodgkin lymphoma that is generally considered indolent, but the disease remains incurable, and the majority of patients eventually relapse," wrote...

​Chimeric antigen receptor (CAR) T-cell therapy is a form of immunotherapy in which a patient's own T cells are collected and genetically altered to target cancer cells. Although CAR T-cell therapies have shown encouraging results in patients with acute lymphoblastic leukemia and B-cell lymphomas, they are associated with several serious adverse events, including cytokine release syndrome, neurotoxicity, tumor lysis syndrome, and graft-versus-host disease.  In light of the growing use of CA...